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Abstract 
With the widespread issue of cardiovascular disease, there is a call for the development of 
technology to help in the recovery of heart attack victims. The development iPSCs alleviates the 
damage experienced by myocardial infarctions. Current research suggests that iPSCs are a 
promising solution to the issue of cardiac repair, and can help regenerate healthy tissue in 
damaged areas. This study aims to explore these possibilities and apply them towards the 
analysis of full manufacture and sale of this technology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Executive Summary 
 Cardiovascular disease has been one of the leading causes of death in the United States 
for over a century. Each year over $108.9 billion is spent to treat patients suffering from 
myocardial infarction. The current methods of heart repair are limited by a lack of technology 
and are challenged by the inability to restore function to dead tissue. Surgical options are 
considered the most effective treatment option at this point in time, yet limitations for these 
procedures still remain. These include rejection of allogeneic tissues, infection, and a limited 
number of organs just to name a few. 
 Stem cells have the potential to overcome these limitations and act as a more effective 
form of treatment for a myocardial infarction. A stem cell is classified as an undifferentiated, 
self-renewing cell that has the potential to differentiate into other types of cells. There are many 
different types of stem cells in the human body including embryonic, mesenchymal, cardiac, and 
induced pluripotent stem cells. In the United States there is still a lot of controversy surrounding 
embryonic stem cells even though techniques have been developed to obtain them without 
destroying the blastocyst. Nonetheless due to this stigma they were not analyzed as part of this 
paper.  
 Mesenchymal stem cells sometimes referred to as bone marrow stem cells, have shown 
the potential for treatment of a heart attack in limited clinical trials where they were found to 
improve ejection fraction. Some studies have shown that they may be limited by an inability to 
accurately target injury sites in vivo. Cardiac stem cells are newly discovered cells that were 
found in a specialized compartment in the heart. There is still a lot to be learned about these 
cells, but they are believed to be involved in homeostasis of the adult heart. They have shown 
promise for treatment in trials on myocardial infarctions in mice as well. The scarce quantities of 
  
these cells in the human body coupled with the lack of research about them are their main 
restricting factors.  
 In 2012 Dr. Shinya Yamanaka and Dr. John B. Gurden were awarded the Nobel Prize in 
medicine for their discovery of induced pluripotent stem cells. These are stem cells that are 
converted from adult epithelial cells into “embryonic-like” stem cells via the overexpression of 
four cellular transcription factors: Oct3/4, Sox2, CMY-C, and KLF4. These cells have the most 
potential to become an effective medical treatment based on the fact that they can be induced 
from adult cells. There have also been studies showing that induction efficiency can be increased 
by using micro RNA to silence induction inhibitors. A very serious concern of this technology is 
that the induction process can stimulate an oncogenic response in cells. Scientists are currently 
investigating the use of alternative transcription factors to avoid this response.  
 A market analysis was conducted in order to understand how profitable these cells could 
potentially be. Many factors needed to be considered to determine this including the state of the 
present industry, the target market, pricing strategy, and potential strengths, weaknesses, 
opportunities, and threats to the technology.  
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1. Background Chapter 
Cardiovascular disease (CVD) has been the leading cause of death in men and women in 
the United States every year since 1900, except in 1918 (influenza was the leading cause this 
year), with coronary heart disease being the most common
1, 3
. An initial heart attack is 
experienced by 785,000 people every year, with 470,000 who have already had a heart attack 
experiencing another later in their life
1
. This puts a $108.9 billion dollar burden on the Unites 
States economy
1
. Ischemic heart failure occurs when the coronary arteries that supply 
oxygenated blood to the heart are blocked
2
. Blockage of the coronary arteries is mainly caused 
by plaque formation that prompts blood platelets to stick together forming a blood clot, or 
complete obstruction of the artery by the plaque
2
. Once the flow of oxygen to the heart is 
impeded, the heart tissue is deprived of oxygen, therefore initiating mass cell death
2
.  
Identifying a heart attack is crucial for survival. Chest pains are the most common 
symptom and may spread to the arms, shoulder, and jaw
2
. Although these symptoms are 
common, this does not mean that they will occur. Elderly people, people with diabetes, and 
women are more likely to experience a phenomenon known as a silent heart attack, where little 
to no chest pain is present
2
. There are several ways to test for heart damage in a patient. 
Electrocardiograms may be used to identify damaged areas or a troponin blood test can show if 
there is tissue damage
2
. After the tissue has been infarcted, the resulting damage can lead to scar 
formation, increased pressure, ventricular remodeling, and ultimately death if left untreated
3
. The 
restoration and regeneration of damaged tissue is therefore the most viable option for optimal 
heart repair
3
. Traditionally heart repair has been challenged by the lack of technology and 
methods needed to completely restore function. Current pharmaceutical treatments involve beta-
  
blockers, diuretics, and angiotensin-converting enzyme inhibitors
3
. Although these treatments 
may relieve the heart from the burden caused by tissue damage, they do not restore function to 
the dead cells
3
. Surgical options can vary from implanting a pacemaker to receiving complete 
organ transplantation
3
. Although the implantation of a mechanical device to assist the heart can 
provide a long-term solution, the fact remains that these devices are prone to infection, 
mechanical failure, and blood clots
3
. The optimal choice currently available for heart infarction 
victims is complete heart transplantation, although problems such as rejection and organ 
accessibility limit the practicality of this option
3
. 
A major concern with any new innovation in the healthcare field is cost and the level of 
coverage by insurance companies for new treatments. Stem Cells, being a rather new technology, 
are expected to be expensive when they come into the market.  
For this project there were two main problems to be considered. The first issue was to 
find the best stem cell of embryonic quality to use in the regeneration and repair of heart tissue. 
These stem cells need to be easily applicable to patients and the issues of rejection, 
compatibility, and timing need to be resolved. The term “of embryonic quality” refers to a 
pluripotent, undifferentiated cell that can be used to treat infected or infarcted areas of the heart. 
It does not mean that actual embryonic stem cells are planned to be used. The use of embryonic 
stem cells as a treatment or remedy remains a very controversial topic in modern medicine.  
The second problem that was considered was the issue of profitability of this technology. This 
was determined by conducting a thorough market analysis of the stem cells including but not 
limited to creating a SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis, studying 
the supply-chain management of the technology, looking at current trends in the marketplace, 
and determining successful marketing strategies. Also, the team will consider looking at the 
  
ethical concerns around embryonic stem cells to see if those concerns carry over to other types of 
stem cells. Currently there is no industrialization process for viable mass production of these 
cells. To determine the profitability of the stem cell product, it is important to assess every stem 
cell from production to administration into the final patient. 
Current Treatment for heart failure 
Current methods for the treatment and prevention of heart attacks are being revised and 
improved upon, but mortality rates still remain high and treatment after an infarction remains 
complicated. It is estimated that in the US there are 1.1 million heart attack survivors every 
year
15
. To date, there are two approaches for the treatment of CVD: a pharmacological approach 
and surgical intervention
14
. The treatment of CVD through pharmacological therapy includes 
using beta-blockers, diuretics and angiotensin-converting enzyme (ACE) inhibitors. These drugs 
are even limited in their usage towards treating CVD. Patients have to meet certain criteria 
involving the extent of the damage, the location of the damage, and the stability of their 
circulation
16
. Furthermore,   ACE inhibitors have to be supported with the intake of angiotensin 
II type 1 receptor blockers
17
. Drug metabolism and neurohormones have to be carefully 
monitored closely when using angiotensin receptor blockers, aldosterone antagonists, beta-
blockers, natriuretic peptides, vasopressin antagonists, tumor necrosis factor inhibitors, and 
neutral endopeptidase inhibitors
14
. Surgical treatment of CVD involves the implantation of 
mechanical devices, surgical alterations of the heart, and in more extreme cases, heart 
transplantation. The current approach in the surgical treatment of CVD includes changing the 
shape of the left ventricle, the implantation of ventricular assist devices (VDA), and pacemaker 
and implantable cardioverter defibrillator (ICD) device implantations
14
. After a patient has 
undergone coronary artery bypass due to ischemic heart failure, they experience a reduction in 
  
end-systolic volume. This makes it necessary for patients to undergo survival ventricular 
reconstruction in addition to the coronary bypass for the regulation of end-systolic volume
18
. 
Until recently, VADs could only be implanted into patients whose chest was large enough to fit 
the device and had end-stage heart failure
19
. Today, VADs can be implanted into either the right 
(RVAD) or left (LVAD) ventricle and the implantable unit can benefit patients with earlier 
stages of heart failure
19. Pace makers and ICDs are regulatory devices that support the heart’s 
electrical system, and regulate the heart’s rhythm20, 21. The methods of treating CVD are not 
methods that restore heart function to infarcted areas, but rather support the damaged heart as a 
whole. Clearly there is a need for the development of a new therapy for CVD that is not as taxing 
on the heart as current treatment methods, with iPSC’s being a likely candidate. 
2. Materials and Methods 
We obtained the information for this project and conducted our research primarily 
through literary review. Books, journals, articles, and actual copies of clinical trials were used for 
various aspects of the project. There were also interviews conducted with people who work in 
the field of stem cells. These people included professionals, students, doctors, and professors. 
 
2.1. Interview Researchers 
The following questions were asked when talking or interviewing individuals that are 
knowledgeable in the respective subject area.  
1. Do you believe that cardiac stem cells are a viable option to repair damaged tissue in the 
heart? 
2. Have you had any specific experience using a particular type of stem cell for heart repair? 
3. If so, what types of cells have you found to be most effective in heart repair? 
  
4. What stage is iPS cell research and development in at the current point in time? 
5. Are there any potential drawbacks to creating and using iPS cells in the heart? 
6. What are all of the costs (time, money, etc.) involved in creating iPS cells? 
7. How far away is this type of research from human clinical trials? 
8. How do iPS cells compare to cardiac stem cells in terms of effectiveness and cost? 
2.2. Market Analysis 
The main parts of the market analysis have to do with target market, operating market and 
the competitive strategy of a business. In the case of this project, the primary focus will be on the 
operating market.  
Target market: 
The target market consists of individuals that will purchase the stem cells. The 
considerations for each patient include age, gender, income level, social class, and education. All 
these factors affect the purchasing quantity of the stem cells for each patient. These target market 
characteristics were all taken into account when determining the level of revenue. 
Operating market: 
Operating market looks at the field of Biology as a whole, not focused around stem cells 
specifically. This includes individual companies that will be manufacturing the stem cells for 
application towards the target market. The attributes considered for the operating market include 
the industry standards and fluxes, the size and purchasing power of each firm, and the quality of 
the technology being produced relative to the price structure. 
 
 
 
 
 
 
  
Competitive Strategy  
 
The competitive strategy looks at analysis of a field of market from the business point of view. 
The tools used to analyze the competitive strategy of a stem cell producing firm was a SWOT 
analysis and the business strategy and its applications 
 
2.3. Current Trends in Market 
 
Looking at the Current trends in the Biology and health care industry our project will 
address the following questions.  
1. Are there any barriers that may hinder entrance into the market? 
2. What is the window of opportunity to enter the market?  
3. Are there any indirect or secondary competitors who may impact your success? 
4. What obstacles exist in the market that need to be addressed in order to achieve success (e.g., 
changing technology, high investment cost, lack of quality personnel, ethics)? 
 
3. Discussion 
3.1. Overview of Potential Stem Cell Types for Repair of Myocardial Infarction 
3.1.1. Stem Cell Types 
There are many types of stem cells that could have viable use for repair of a myocardial 
infarction. These include embryonic stem cells, mesenchymal stem cells, and cardiac stem cells. 
Embryonic stem cells are undifferentiated, pluripotent cells derived from the embryo of a fetus 
prior to differentiation. Currently most methods for harvesting embryonic stem cells are 
controversial due to various legal and ethical issues. Consequently, we do not believe that there 
is a very large market for these cells at this time. 
  
Mesenchymal stem cells are most commonly classified as "bone marrow" stem cells, but 
similar types of stem cells are also found in adipose, umbilical cord blood, skeletal muscle, and 
other tissues
9
. Recently there has been some very promising research showing that these stem 
cells could be utilized for regenerative medical purposes, including, but not limited to treatment 
of tissue damaged during myocardial infarction. The International Society for Cellular Therapy 
(ISCT) has defined human mesenchymal stem cells, or hMSC’s, by a series of criteria.  
First these cells need to have a presence of certain cell markers. Cell markers are 
commonly named based on their clusters of differentiation (CD) followed by a number based on 
the order of when they were discovered. Clusters of differentiation are defined as clusters of 
antigen that are present on the surface of the cell. Cells that display a presence of cell markers 
CD73, CD90, and CD105 (in vitro) fulfill the first classification criteria. The second criteria say 
that they must display less than 2% of cell markers CD45, CD34, CD14, and CD19
9
. This is 
because these cell markers are associated with other tissues in the body that are not derived from 
bone marrow. Lastly a human mesenchymal stem cell must show an adherence to plastic and 
have multi-lineage potential meaning that they could develop into ectoderm, mesoderm, or 
endoderm
9
. 
At this time most testing of hMSC’s has only been done in vitro, but one clinical trial 
investigating their effectiveness in the treatment of a myocardial infarction showed promising 
results. A group of 53 heart attack patients, whose hearts were injected intravenously with MSCs 
shortly after infarction experienced an improved heart and lung function
9
. More specifically 
three randomized concentrations of stem cells (0.5 million, 1.6 million, or 5 million MSCs/kg 
respectively) were administered into patients and compared against a placebo. Effectiveness was 
measured using echocardiography and the results showed a large improvement in ejection 
  
fraction, or the amount of blood pumped from the heart in a single heartbeat, in hearts that 
received the stem cell treatments. Despite this there still needs to be more research conducted to 
determine the ideal concentration of mesenchymal stem cells to use. Furthermore there has been 
research that suggests that these stem cells tend to be very inefficient at targeting injury sites in 
the heart for various reasons such as becoming entrapped in the lungs before they reach the target 
site
10. This has led to the theory that these hMSC’s ability to heal injured tissue may not be due 
to differentiation into cardiac tissue, but instead may be caused by their secretion of factors that 
induce repair mechanisms such as angiogenesis
9
. Based on the reasons above we did not believe 
that hMSC’s would be the optimal stem cell type for heart repair. 
Until recently, the heart was considered to be post-mitotic and unable to regenerate. 
Researchers have identified human cardiac progenitor cells that could be used in the rebuilding 
of generating cardiomyocytes and coronary vessels
4
. These cells have mostly been found to 
differentiate into cardiomyocytes, but may also become smooth muscle cells and endothelial 
cells
5
. Recently the heart has been identified as an organ regulated by stem cells. Located in a 
"stem cell compartment" inside of the heart, human cardiac stem cells, or hCSC’s have been 
discovered to be involved in postnatal development as well as the regulation of homeostasis in 
adult hearts
11. Initially hCSC’s were classified as bone marrow stem cells that had made their 
way into the heart, but after some closer analysis it was shown that this was not the case. These 
cells were shown to co-express the stem cell antigen c-kit as well as some myocyte transcription 
factors. Importantly, these cells did not contain CD45 or KDR which are common bone marrow 
cell markers
11. This shows that hCSC’s are not the same as bone marrow stem cells. 
In trials on mice, hCSC’s have shown some promising results. Infarcted mouse hearts 
were injected with hCSC’s shortly after cardiac arrest which resulted in the generation of a 
  
chimeric heart that included human myocytes and coronary vessels
11
. This regenerated tissue 
was shown to cause improvement of ventricular function and increased ejection fraction, despite 
the fact that these human tissues were formed independently of mouse tissue and that no cellular 
fusion had occurred. Although resident CSC’s become present after a myocardial infarction, they 
typically have little to no regenerative effect because the majority of them in the damaged 
portion of the heart die along with the other cells that are damaged
11
. Other limitations of these 
stem cells are that they are limited to a compartment in the heart therefore their availability is 
relatively scarce. There are also a lot of unanswered questions about hCSC’s such as their in vivo 
capabilities that need to be answered before more clinical trials should begin. 
3.1.2. iPSC’s 
 In 2012 Dr. Shinya Yamanaka and Dr. John B. Gurden were awarded the Nobel Prize in 
medicine for discovering how to turn adult epithelial cells into embryonic-like stem cells
7
. These 
cells are known as induced pluripotent stem cells. Induced pluripotency is achieved by using a 
virus to cause the overexpression of four cellular transcription factors: OCT3/4, SOX2, CMY-C, 
and KLF4. Evidence has been shown that there are also four alternative transcription factors that 
can lead to cellular reprogramming as well. These are Oct4, Nanog, Lin28, and Sox2; although 
further research is still needed to better understand these factors
12
. Usually after a few weeks of 
infection with the retrovirus, adult somatic cells begin to change their structure and express a 
human embryonic stem cell genetic profile
8
. For the purposes of this paper we have decided to 
use iPSC’s to conduct our market analysis because we believe that they offer the most promise 
for the repair of damaged tissue in an ischemic heart after infarction. We also believe that these 
cells would be the best candidate for eventual mass production. 
  
Induced pluripotent stem cells have been tested to treat sickle cell anemia, Parkinson's 
disease, and hemophilia in the past but have just recently begun to be studied in cardiac 
medicine
13
. In one study conducted on mice that compared iPSC treatments versus fibroblast 
treatments to repair an acute myocardial infarction, iPSC’s proved to be very effective. The 
treatment involved the "intramyocardial transplant" of 200,000 iPS cells into each heart and 
resulted in overall significantly improved heart function compared to hearts that were treated 
with cardiac fibroblasts
13
. This restored function was classified as improved fractional 
shortening, lack of aneurysmal formation, and an absence of severe wall thinning
13
. Even though 
iPSC research is still in its preliminary stages, iPSC’s have been shown to be effective in the 
treatment of myocardial infarction. 
There has recently been an influx of new information in the scientific community 
regarding iPSC generation efficiency. One of the more interesting areas of research is the effect 
of microRNAs on the induction process. Micro RNA, or miRNA, are short, single stranded RNA 
that assist in various reactions in the body. It has been discovered that during the early stages of 
reprogramming three specific miRNA clusters are induced: miR17~92, miR106b~25, and 
miR106a~363. Simultaneous to the induction of these miRNA’s, certain tumorigenic inhibitors 
of reprogramming: Tgfbr2 and p21 become present as well
12
. 
Table 1 
Inhibitors and Aids of Reprogramming 
Reprogramming Inhibitors Reprograming Aids 
Tgfbr2 miR-106b 
p21 miR-93 
The table above shows the reaction inhibitors and the micro RNA that silence them during reprogramming, thereby 
aiding in the efficiency of the induction process. 
 
 
  
The presence of the inhibitor p21 is believed to be caused by a misexpression of Klf4 and 
cMyc. Inhibitor p21 promotes cell cycle arrest during iPSC induction, thus having a negative 
effect on the efficiency of the reaction. Tgfbr2 also acts as an antagonist during induction. 
Specifically miR-93 and miR-106b have been shown to enhance reprogramming efficiency by 
silencing these inhibitors
12
. By adding more of these miRNA during the reprogramming process 
scientists have been able to increase iPSC generation 4-6 fold
12
. As an aside, it is interesting to 
note that p21 has been discovered to be targeted by miRNA from the miR106b~25 cluster in 
cancer research as well
12
. Although there is still much more to learn about the induction of 
pluripotent stem cells, there is hope that learning to utilize miRNA’s during the process could 
someday play an integral role in the mass generation of iPSC’s.  
 
3.1.3. iPSC potentials                                                                        
One of the biggest downsides of organ and tissue transplants is that they are limited in 
their aspects of availability. Biocompatibility of the transplanted organs also becomes a serious 
concern since most donors are not related. Rejection of the organ by the recipient is a very 
serious threat, making life-long treatment with immunosuppressive drugs necessary. Induced 
pluripotent stem cells avoid these complications because the tissue or organ would be generated 
from the patients’ own cells22. The potentials for iPSC’s include the repair of disease-causing 
mutations and drug development
22
. Repair of genetic and degenerative disorders can be achieved 
through transplantable cells in which the gene expression is changed
23
. As previously mentioned, 
iPSC’s have been shown to effectively treat genetic disorders, specifically sickle cell anemia and 
hemophilia, in mice through gene targeting
22,23
. Endothelial cells were cultivated from mice with 
sickle cell anemia and hemophilia, reprogrammed into iPSC’s using gene targeting, and 
  
transplanted into the mice
23
. The resulting reprogrammed healthy progenitor cells produced 
equally healthy red blood cells, and consequently cured the diseases
22,23
. This method can be 
replicated with other genetic disorders and could one day be applied to human trials. 
Drug development through cultures of iPSC’s is an area of research that shows great 
potential as well. This is due to the wide differentiation capabilities of induced pluripotent stem 
cells in vitro
22
. Many degenerative diseases are challenging to study and treat due to the limited 
accessibility of the affected tissues. Induced pluripotent stem cells have the potential to be 
differentiated into diseased cells, thereby eliminating the need for biopsied cells. Using iPSC’s to 
study these disorders can also allow for diseases to be studied at earlier stages. This is because in 
most scenarios by the time a patient's tissue is studied, the disease is already well into its later 
stages. Scientists believe that iPSC’s could be differentiated into diseased cells and will behave 
the same way as regular somatic cells going through the same stages of infection. It is evident 
that iPSC’s could potentially be utilized in the identification of new drugs to treat degenerative 
diseases without surgical intrusion into the patient or constant biopsies
22
. Recent clinical research 
has already shown promise in treating patients suffering from spinal muscular atrophy (SMA), 
familial dysautonomia, and multiple lentigines syndrome using patient derived iPSC’s to 
recapitulate the disease
22
.   
3.1.4. Current complications with iPSC’s 
In order for these induced pluripotent stem cells to be integrated into wider clinical and human 
research applications, there are issues that still need to be addressed:  
● The creation of pluripotent cells from donor epithelial cells using manipulation 
techniques is less efficient in humans than in the mouse, blocking the integration of iPSCs into 
medical consumer markets for gene targeting
24
.  
  
● iPSC’s still cannot be generated without alterations to the genome 
● Not all cell types have been shown to be able to be differentiated from induced 
pluripotent stem cells 
● Quality assessment of in vitro derived cells versus in vivo derived counterparts 
● Efficiency and methods for generating iPSC’s in a high-throughput and high quality 
manner
24
. 
● Residual oncogenetic factors could be expressed in the transplant patient, leading to 
cancerous tumors. 
 
 
3.2. Marketing Analysis: 
A market analysis is used to look at the potential feasibility of using therapeutic induced 
pluripotent stem cells to treat cardiovascular disease as regenerative medicine. The market 
analysis uses several tests to determine the current state of the biotechnology and medical 
markets and how the introduction of a new product will affect these markets.  
3.2.1. Industry Analysis 
The industry analysis looks at the current state of the market, looking at its present size, 
projected growth rates, trends and characteristics. In the case of induced pluripotent stem cells 
several industries have to be considered, such as the medical/healthcare, biotechnology and 
pharmaceutical
6
. These three industries all play a role as the medical industry will use stem cells 
to treat patients, the biotechnology industry will produce them, and the pharmaceutical will sell 
them.  
  
 
Figure 1 Medical Industry Projections 
Figure one looks at the projected growth by year in the medical industry. The medical 
and healthcare industry represents consumer spending on healthcare and health services, such as 
medical practices, hospital fees and other human health fees. . This market is expected to grow 5-
6% ever year for the next four years
6
. Some of the factors that are hindering the growth rate 
include insurance companies’ attempts to control the medical costs.  
3.2.2. Stakeholders Analysis 
A stakeholder’s analysis looks at the groups that have both power and influence over a 
given product in the market. The analysis directly looks at who has the most power to shape the 
products and who will influence its success. An X-Y Axis is used to demonstrate power and 
influence.  
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Figure 2 Stakeholder’s Analysis of Induced Stem Cells 
 
 Figure 2 looks at the direct power and influence that insurance companies, pharmaceutical 
companies, medical professions and patients have over the commercialized sale of iPSCs on the 
market. Insurance companies have a high level of influence and power, as they will cover the 
costs for the patients receiving treatment. Pharmaceutical companies are placed in the high 
power group because they will most likely sell the product to the patients. Physicians and 
medical professionals tend to have a high level of influence because they will be using the 
product, but they are limited to using medical procedures that are covered by insurance since this 
is how the majority of consumers pay for healthcare. Patients are low power and influence, they 
are people that need to be considered in the making of the product, but in the end have no power 
to change the product sales, or influence in changing the treatment methods.  
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3.2.3. Target Market 
The target market analysis looks at what group of consumers the iPSC's are marketed 
towards. There are several key factors to consider when looking at stem cells. First and foremost 
is the use of the product. There are several key practices that scientists and healthcare 
professionals will use stem cells for including medical research, genetic disease treatments, 
regenerative tissues, and drug research. The resulting effects of this new technology have the 
potential to be revolutionary as numerous diseases formerly termed “incurable” would be 
treatable with the development of fully induced pluripotent stem cells
25
.  
There are several key customer groups that will affect the development of marketing stem 
cells. The first major customer has to be insurance companies, because chances are that the end 
product will be too expensive for the general public to purchase, at least in the starting stages of 
production
29
. Scientists, drug development companies, and wealthy consumers who could bypass 
insurance companies to purchase iPSCs on their own are also part of the target market.
 
 
 
 
3.2.4. Cost Analysis 
Therapeutic iPSC have large variable costs associated with taking cells from the patient, 
in the form of a biopsy and reprograming those cells into pluripotent stem cells
27
. Determining 
the cost of all the supplies was based on the following production line and the recommended 
supplies for these processes. The list price was used and discounts based off of mass production 
were not considered, as therapeutic iPSCs for cardiac treatment are not currently ready for mass 
production
27
.  
  
 
Figure 3 Process of Therapeutic iPSC 
 
The income statements of several mid-sized biotechnology companies were used to 
examine the fixed cost with the exception of specific equipment which is unique to the iPSC 
process. Research and development are essential to a biotech company which is why almost 50% 
of total costs were used for this business discipline. The fixed costs in this analysis are also based 
off of the first month, as some of the items are one time costs and others may vary month to 
month (research and development). The cost for one employee was determined based on the 
hourly rate for an employee with four to eight year experience in the field of biotechnology
28
. 
General administration costs take into account the wages of non-hourly employees of the 
company who are not working directly on the project, but are still doing related activities.  
 
 
 
Cost Induced Pluripotent Stem Cells Cost 
Variable Costs 
 
Patient Biopsy 
Cultured Adult 
Cells 
Safe 
Reprogramming 
iPSC Differentiation Therapeutic Cells 
  
Patient Biopsy  $        360.00  
Biotech Employee @ $23.22 per Hour  $        115.00 
Materials 
 CytoTune®-iPS Sendai Reprogramming Kit   $    2,055.00  
Episomal iPSC Reprogramming Vectors  $        755.00  
TaqMan® iPSC Sendai Detection Kit  $        350.00  
Serum Replacement  $          30.00 
hESC SFM  $        260.00 
Essential 8 Medium  $        195.00 
XenoFree ESC/iPSC kit  $        782.00  
Neurobasal™-A Medium  $          58.00  
N-2 Supplement  $          69.00  
G-5 Supplement  $          57.00  
ELF® 97 Endogenous Phosphatase Detection Kit  $        350.00  
TaqMan® Array Human Stem Cell Pluripotency Panel  $    1,539.00  
  
  
  Fixed Costs 
 Research and Development  $  22,000.00  
General Administration  $    5,240.00  
Rent  $    1,500.00  
Utilities  $        650.00  
Equipment 
 Neon® Transfection System  $    6,975.00  
Other  $    4,500.00  
Total Costs  $  47,835.00 
 
Figure 4 Total Cost of Producing Induced Pluripotent Stem cells of Therapeutic Quality 
Figure 4 determines that the total cost for producing one round of therapeutic quality 
stem cells would be $47,830.00
28
. This cost, although fairly accurate, can not be a perfect 
estimation as this technology is not currently on the market for mass production and some of 
these numbers are estimates.  
After the total cost was calculated, the cost for units produced was displayed in 
increments of 50. A large number was used due to the large number of cardiac problems per 
month in the United States. On Average, there are 77,900
1
 heart problems per month. Induced 
  
pluripotent stem cells have the potential to be the most effective treatment for damaged cardiac 
tissue. For this analysis, it will be assumed that one employee could handle 25 samples during 
one cycle.  
 
3.2.5. Break Even Analysis 
Income Statement  Amount $ 
14 Units Sold 
 
  Revenue  $          140,000.00  
  Variable Costs  $             97,565.00  
  
  Gross Margin  $             42,440.00  
  
  Fixed Costs  $             40,864.00  
  
  
  Net Income  $               1,575.00  
Figure 5 Income Statement for Break Even Analysis Selling price at $10,000 per unit 
 
A break-even analysis was used to determine the number of units that would need to be 
sold to turn a profit. A unit is considered one group of therapeutic stem cells that could be used 
to treat patient’s cardiac problems. The price of one unit sold was set at $10,000 (see section 
4.1.6). The main reason why the break even point is low, fourteen units, is because the gross 
margin for each unit sold is about $3,000 and the fixed cost is relatively low compared to the 
variable costs.  
3.2.6. Pricing Strategy  
 
  
Income Statement  Amount $ 
25,000 Units Sold 77,900 Heart Attacks per month 
  Revenue  $          250,000,000.00  
  Variable Costs  $          174,219,500.00  
  
  Gross Margin  $            75,780,500.00  
  
  Fixed Costs  $                     40,864.00  
  
  
  Net Income  $            75,739,636.00  
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Figure 6 Income Statement for 50,000 units sold per month; selling price at $10,000 per 
unit. 
A selling price of $10,000 was used during the break-even and mass production prices. 
The reasoning for this price to be used is because it would be comparable to a bypass surgery 
except that the 10-day hospital admission would be reduced to 3 days. Each hospital admission is 
$1800 plus $3,715 for physician’s fee and $2,500 anesthesia services which adds to $11,61025,28. 
 
 
 
3.2.7. SWOT Analysis  
A SWOT analysis (which stands for strengths, weaknesses, opportunities and threats) was used 
to look at a potential iPSC company’s strengths and weaknesses in comparison to its main 
competitors. For the purpose of this analysis, we assumed that the company is the only company 
  
that is selling iPSCs on the market and related it to other treatment methods from various other 
companies.  
 
 Figure 7 SWOT Analysis for iPSC product 
 The SWOT analysis in figure 7 indicated several benefits of iPSCs for producers of the 
treatment. The strengths of this new technology come from the fact that it has the potential for 
higher success in modern medical treatments as well as improved biocompatibility and reduced 
hospital fees compared to the current treatment options available. Current issues that could 
threaten the success of induced pluripotent stem cells are reluctant insurance companies, delays 
in research and funding, and the potential oncogenic nature of stem cells.  
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3.2.8. Treatment Cost Analysis 
Treatments In-hospital Costs 
Pharmaceutical 
Costs 
Total 
costs 
    
iPSC 
$                 
10,000.00  
$                         
1,700.00  
$      
11,700.00  
    1. Cardiovascular Disease 
   
 a. Lifestyle Changes 
$                                
-    
$                                     
-    
 
 b. Medications  
 $                                
-    
 $                         
1,700.00  
  c. Surgery 
   
    i. Coronary angioplasty 
$                 
22,768.00  
$                                     
-    
$      
24,468.00  
    ii. Coronary artery bypass 
 $                 
63,648.00  
 $                                      
-    
$      
65,348.00  
 
 
   2. Heart Defect Treatments 
   
a. Medications 
 
$                         
1,700.00  
 
b. Open Heart Surgery 
$              
324,000.00  
 $                                     
-    
$   
325,700.00  
c. Heart Transplant 
 $              
977,700.00  
 $                                      
-    
$   
977,700.00  
 
 
   3. Cardiomyopathy Treatments 
   
a. Medications 
$                                
-    
$                         
1,700.00  
 
b. Medical devices 
 $                 
22,735.00  
 $                                     
-    
$      
24,435.00  
c. Heart Transplant 
 $              
977,700.00  
 $                                      
-    
$   
979,400.00  
 
 
   4. Valvular Heart Disease 
Treatments 
   
a. Medications 
$                                
-    
$                         
1,700.00  
 
b. Valve repair  
 $                 
35,976.00  
 $                                     
-    
$      
37,676.00  
26 
Figure 8 Treatment Cost Comparison  
 
  
Figure 8 looks at all current forms of treatment on the market in comparison to iPSCs. 
Heart transplants and open-heart surgery are among the most expensive and invasive surgeries 
on the market. Stem cells will reduce the number of invasive surgeries performed each year 
which will shorten patient recovery times and improve patient turnover rates in hospitals
25
. 
Virtually all surgeries and treatments have pharmaceutical costs of some sort
26
. Pharmaceutical 
costs will remain with the new technology as well because iPSC treatment will only regenerate 
damaged tissue, not prevent the problems
29
. Although a combination of lifestyle changes and 
iPSCs would be the lowest costing treatment for a patient recovering from a myocardial 
infarction; short term medications still need to be taken after the initial heart attack to ensure that 
the healing process goes as planned. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Conclusion 
With the right economic opportunities as described in this paper, Induced Pluripotent Stem Cells 
have a viable future in regards to advancing regenerative medicine for the application of cardiac 
repair. Because iPSCs are autologous and are not surrounded with political and religious 
polarization, they are optimal in treating infarcted areas of the heart. Due to the cells being 
autologous, availability for treating damaged areas in the heart will no longer be an issue, along 
with worries of biocompatibility and tissue rejection. Although research of iPSCs and their 
application in treating cardiovascular disease is still in the developing stages, it is showing 
promise for the treatment of myocardial infarctions. The current complications with developing 
iPSC are genetic in nature and have more to do with efficiency, the largest of which is the 
undesired expression of oncogenetic factors in the cell.  
Current market research suggests that Induced Pluripotent Stem Cells have a high production 
cost, a reality that could inhibit the proliferation of this technology into current medical practices. 
If these cells could be mass produced and were FDA cleared for application towards treating 
cardiovascular disease, there exists a possibility of considerable revenue for a company that 
penetrates the market.  
The promises held by iPSCs have not been fully ascertained, as everyday research is being done 
on their effects. Procedural practices, including medical, manufacturing, biological, and business 
procedures have not been perfected. The advances that these stem cells hold are innumerable, as 
they can be applied in the treatment of numerous other diseases. Over 700,000 heart attacks 
happen in the United States every year, a number that cannot be lessened with current medical 
and pharmaceutical technology. The hope of being able to treat all these infarcts lies with the 
development and propagation of Induced Pluripotent Stem Cells in current medical practices. 
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